Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;42(7):473-481.
doi: 10.1016/j.revmed.2020.12.015. Epub 2021 Jan 27.

[Common variable immunodeficiency disorders: Part 2. Updated clinical manifestations and therapeutic management]

[Article in French]
Affiliations

[Common variable immunodeficiency disorders: Part 2. Updated clinical manifestations and therapeutic management]

[Article in French]
J F Viallard et al. Rev Med Interne. 2021 Jul.

Abstract

Common variable immunodeficiency disorders (CVID) are the most common symptomatic primary antibody deficiency in adults with an estimated prevalence of 1/25,000. The most frequent clinical manifestations are upper respiratory tract infections (including pneumonia, bronchitis, and sinusitis) predominantly with Streptococcus pneumoniae or H. influenzae. However, CVID are complicated in 20 to 30 % of cases of non-infectious manifestations which have been well characterized in recent years. Several complications can be observed including autoimmune, lymphoproliferative, granulomatous or cancerous manifestations involving one or more organs. These complications, mostly antibody-mediated cytopenias, are correlated with a decrease in the number of circulating switched memory B cells. Replacement therapy with polyvalent gammaglobulins has greatly improved the prognosis of these patients but it remains poor in the presence of digestive complications (especially in the case of chronic enteropathy and/or porto-sinusoidal vascular disease), pulmonary complications (bronchiectasis and/or granulomatous lymphocytic interstitial lung disease) and when progression to lymphoma. Much progress is still to be made, in particular on the therapeutic management of non-infectious complications which should benefit in the future from targeted treatments based on knowledge of genetics and immunology.

Keywords: Autoimmune cytopenias; Common variable immunodeficiency disorders; Cytopénies auto-immunes; Déficit immunitaire commun variable; Granulomatose; Granulomatous disease; Immunoglobulins replacement therapy; Maladie vasculaire porto-sinusoïdale; Porto-sinusoidal vascular disease; Substitution par immunoglobulines.

PubMed Disclaimer

MeSH terms

LinkOut - more resources